Stockscreener 앱 받기
2.345
2.29%
-0.055
전일 마감가:
$2.40
열려 있는:
$2.4
하루 거래량:
144.08K
Relative Volume:
0.21
시가총액:
$65.22M
수익:
$50,000
순이익/손실:
$-41.60M
주가수익비율:
-1.3838
EPS:
-1.6946
순현금흐름:
$-20.20M
1주 성능:
+1.08%
1개월 성능:
+37.13%
6개월 성능:
+81.78%
1년 성능:
+12.20%
1일 변동 폭
$2.3009
$2.45
1주일 범위
$2.24
$2.499
52주 변동 폭
$1.09
$2.499
Inmune Bio Inc Stock (INMB) Company Profile
명칭
Inmune Bio Inc
전화
(858) 964-3720
주소
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Compare INMB vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
2.35 | 59.95M | 50,000 | -41.60M | -20.20M | -1.6946 |
VRTX
Vertex Pharmaceuticals Inc
|
542.85 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
790.88 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,028.51 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.21 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
206.73 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-01 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2025-07-01 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Underperform |
| 2025-01-28 | 개시 | Rodman & Renshaw | Buy |
| 2024-10-21 | 개시 | Alliance Global Partners | Buy |
| 2024-09-27 | 개시 | Raymond James | Outperform |
| 2024-08-22 | 개시 | Scotiabank | Sector Outperform |
| 2023-06-01 | 개시 | Robert W. Baird | Outperform |
| 2022-05-24 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-07-07 | 재확인 | Maxim Group | Buy |
| 2021-04-21 | 개시 | B. Riley Securities | Buy |
| 2021-01-22 | 재확인 | Maxim Group | Buy |
| 2020-09-01 | 개시 | BTIG Research | Buy |
| 2020-07-15 | 재확인 | H.C. Wainwright | Buy |
모두보기
Inmune Bio Inc 주식(INMB)의 최신 뉴스
INMB Stock Gained 3% Today – What Did The FDA Say About Its Alzheimer’s Trial? - Stocktwits
Inmune Stock Price Forecast. Should You Buy INMB? - StockInvest.us
INmune Bio Inc (INMB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
INmune Bio (INMB) Q2 2026 Earnings Call Transcript - AOL.com
INmune Bio Advances Ebstrocel Regulatory Filings and Clinical Plans - sekbernews.id
INmune Bio (NASDAQ:INMB) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Q2 2026 INmune Bio Inc Earnings Call Transcript - GuruFocus
Earnings call transcript: INmune Bio posts narrower Q2 2026 loss, eyes filings - Investing.com South Africa
INmune Bio, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
INmune Bio Inc (INMB) (Q2 2026) Earnings Call Highlights: Regula - GuruFocus
INmune Bio Inc (INMB) (Q2 2026) Earnings Call Highlights: Regulatory Wins and Strategic Focus ... - Yahoo Finance
INmune Bio Q2 Earnings Call Highlights - MarketBeat
INmune Bio Q2 2026 Earnings: Tax-Credit Benefit Narrows Net Loss - TradingKey
INmune Bio (NASDAQ:INMB) Releases Quarterly Earnings Results, Beats Expectations By $0.16 EPS - MarketBeat
INMB: Ebstrocel nears global filings as financials strengthen and XPro advances in Alzheimer's - TradingView
INmune Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress - The Manila Times
Inmune Bio, Inc. Q2 2026: Revenue $0 Net loss $(1.27)M, EPS $(0.05) — 10-Q Summary - TradingView
INmune Bio Q2 net loss narrows on lower impairment charges - TradingView
INmune Bio (NASDAQ: INMB) posts $6.7M loss and warns on cash runway - Stock Titan
INmune Bio Inc expected to post a loss of 21 cents a shareEarnings Preview - TradingView
INmune Bio receives $4.6M in R&D rebates from Australia, UK - Investing.com UK
INmune Bio Strengthens Cash Runway With R&D Rebates - TipRanks
INmune Bio receives ~$4.6M in R&D rebates, cash proceeds exceed Q2 operating cash use - TradingView
INmune Bio (INMB.US) will release its earnings report after market close on August 6. - moomoo.com
INmune Bio Inc.Common stock (INMB) Stock Price, News, Quote & History - FinancialContent
INmune Bio Receives $4.2 Million Australia R&D Rebate, Extending Cash Runway for CORDStrom Development - Quiver Quantitative
INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on ... - Caledonian Record
INmune Bio schedules Aug. 6 webcast on second-quarter results - Stock Titan
INmune Bio forms scientific advisory board for cell therapy By Investing.com - Investing.com Nigeria
INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform - Yahoo Finance
INMB Q2'26 Earnings: revenue estimate is 0 USD - TradingView
INMB|INmune Bio Inc|Price:1.745|Chg%:+0.125 - TradingKey
INmune Bio Inc. (INMB) Holds Steady at $1.73 as Traders Eye Defined Trading RangeVOLD Alert - vinanet.vn
INmune Bio Inc (INMB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
INmune Bio Inc (INMB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
INmune Bio Inc (INMB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
INMB|INmune Bio Inc|Price:1.620|Chg%:-0.100 - TradingKey
INmune Bio Inc (INMB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
INmune Bio Inc (INMB) Valuation: PE, PB & Fair Value Analysis - TradingKey
TradingKey - TradingKey
INmune Bio Inc (INMB) Institutional Confidence - TradingKey
INmune Bio Inc (INMB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
INmune Bio (INMB) Slides 4% Amidst Subdued Trading, Testing Support at $1.57Straddle Setup - vinanet.vn
INmune Bio (INMB) Slides 6.5% as Selling Pressure Mounts, Tests Key Support at $1.63Investment Factor - dars.gov.et
Inmune Bio stock trades on Nasdaq as investors watch trial progress and cash runway - Ad-hoc-news.de
INMB Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline Amid No RevenueMargin Compression Risk - vinanet.vn
INMB Achieves Breakthrough in Umbilical Cord Tissue Processing - GuruFocus
INmune Bio (INMB) Slides as Bearish Pressure Intensifies Following 3.77% DeclinePCR Extreme - dars.gov.et
INmune Bio And 2 Other Promising Penny Stocks To Consider - webull.com
INmune Bio Achieves Commercial-Ready Manufacturing Milestone for CORDStrom Platform Ahead of Planned Phase 3 Trial - Quiver Quantitative
Inmune Bio Inc (INMB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.38%
자본화:
|
볼륨(24시간):